Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Teprotumumab

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Horizon`s Biologics Tepezza Receives Suppl Approval in US
    Horizon`s Biologics Tepezza Receives Suppl Approval in US

    09 Sep 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761143

    FDA
    09 Sep 2025
    Share Share
    Horizon’s Biologics Tepezza Receives Suppl Approval in US
    Horizon’s Biologics Tepezza Receives Suppl Approval in US

    26 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761143

    FDA
    26 Aug 2025
    Share Share
    Amgen`s Tepezza Receives Approval in Europe
    Amgen`s Tepezza Receives Approval in Europe

    19 Jun 2025

    // EMA

    https://www.ema.europa.eu/en/documents/overview/tepezza-epar-medicine-overview_en.pdf

    EMA
    19 Jun 2025
    Share Share
    Amgen's Tepezza Granted Marketing Authorisation in UK
    Amgen's Tepezza Granted Marketing Authorisation in UK

    07 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250507246547/en/Amgens-TEPEZZA-teprotumumab-Granted-Marketing-Authorisation-as-the-First-Targeted-Treatment-Specifically-for-Adults-With-Moderate-to-severe-Thyroid-Eye-Disease-TED-in-the-United-Kingdom

    BUSINESSWIRE
    07 May 2025
    Share Share
    Leo Pharma`s Tepezza Approved in Canada
    Leo Pharma`s Tepezza Approved in Canada

    17 Apr 2025

    // HEALTH CANADA

    https://pdf.hres.ca/dpd_pm/00080354.PDF

    HEALTH CANADA
    17 Apr 2025
    Share Share
    Innovent's SYCUME® Approved by NMPA for Thyroid Eye Disease
    Innovent's SYCUME® Approved by NMPA for Thyroid Eye Disease

    14 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chinas-first-igf-1r-monoclonal-antibody-innovent-announces-nmpa-approval-of-sycume-for-the-treatment-of-thyroid-eye-disease-302401791.html

    PR NEWSWIRE
    14 Mar 2025
    Share Share